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The deregulation of the homeobox genes as homeoboxB
(HOXB)-7 has been previously associated to tumor progression
and angiogenesis; here we investigated the potential role of
HOXB7 in the pro-angiogenic properties of multiple myeloma
(MM) cells. We found that HOXB7 was expressed in 10 out of 22
MM patients analyzed at the diagnosis related to high bone
marrow angiogenesis and overexpressed in about 40% of
myeloma cell lines compared with normal plasma cells.
Enforced HOXB7 expression in MM cells by a lentiviral vector
significantly modified their transcriptional and angiogenic
profile, checked by combined microarray and angiogenesis
PCR analyses, upregulating VEGFA, FGF2, MMP2, WNT5a and
PDGFA and downregulating thrombospoindin-2. The pro- and
anti-angiogenic HOXB7-related gene signature was also
validated in a large independent dataset of MM patients.
Accordingly, MM-induced vessel formation was significantly
increased by HOXB7 overexpression both in vitro angiogenic
and chorioallantoic membrane assays, as well as the HOXB7
silencing by small interfering RNA inhibited the production of
angiogenic factors, and the pro-angiogenic properties of MM
cells. Finally, in SCID-NOD mice we confirmed that HOXB7
overexpression by MM cells stimulated tumor growth,
increased MM-associated angiogenesis and the expression of
pro-angiogenic genes by microarray analysis supporting the
critical role of HOXB7 in the angiogenic switch in MM.
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Introduction
Bone marrow (BM) angiogenesis is typically increased in
multiple myeloma (MM) patients in relationship with disease
progression being involved in the support of MM cell growth
and survival.1–7 MM-induced angiogenic switch is mainly
sustained by the overproduction of pro-angiogenic factors by
MM cells or the BM microenvironment2,8 as the vascular
endothelial growth factors (VEGF),2,8–10 basic fibroblast growth
factor (bFGF),11 interleukin-8 (IL-8),12 angiopoietin-1,13 and
osteopontin (OPN).14 Other factors secreted by MM cells may
contribute to the angiogenic process including the matrix
metalloproteinases (MMPs),1,15,16 particularly MMP-2, that has
been correlated with MM disease progression.1
However, the molecular mechanisms involved in the regula-
tion of the angiogenic switch and in the production of the pro-
angiogenic molecules by MM cells are not completely known
being still under investigation.
The deregulation of the homeoboxB (HOXB) genes has been
previously correlated to the angiogenic process, as well as to
tumoral-induced neoangiogenesis and tumor progression in solid
cancers.17–22 Particularly, the overexpression of the homeobox
HOXB7 has been associated to tumor-related angiogenic switch,
cell proliferation and the production of bFGF by breast cancer and
melanoma cells.18–22 In addition, it has been reported that HOXB7
overexpression may also regulate VEGF, IL-8 and Ang-2 by tumor
cells.18 Interestingly, we have recently shown that HOXB7 is
overexpressed in BM microenvironment cells of MM patients as
compared with healthy subjects,23 suggesting its potential role in
MM pathophysiology.
Based on all the evidences, to clarify the molecular
mechanisms underlying the angiogenic process in MM, in this
study we have investigated the expression of HOXB7 by
malignant plasma cells (PCs) and its potential role in the
production of pro-angiogenic factors as well as in MM-induced
angiogenesis in vitro and in vivo.
Materials and methods
CD138þ PCs purification from MM patients and
controls
CD138þ PC were purified by BM aspirates (5 ml) obtained from
iliac crest of 22 consecutive patients (median age 66 years;
range 53–73) with newly diagnosed MM (ISS stage I–III) by an
immuno-magnetic method using anti-CD138 monoclonal anti-
body (Ab)-coated microbeads (MACS, Miltenyi Biotec, Bergisch-
Gladbach, Germany). Normal PCs were isolated from both
reactive tonsils and BM aspirates from healthy subjects under-
gone to hip surgery after informed consent according to the
Declaration of Helsinki. Approval was obtained from the
Institutional Reviewer Board of our Hospital. Only samples
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with purity 4of 90% checked by flow cytometry (FACScan,
Becton Dickinson; San Jose, CA, USA) were tested.
Cell culture conditions
Cell lines. Human myeloma cell lines (HMCLs) were
obtained: RPMI-8226 from DSMZ collection (Braunschweig,
Germany), JJN3 were kindly provided by Dr Bataille Regis
(INSERM, Nantes, France); KMS-27, KMS12 and KMS-20 from
Dr Otsuki (Medical School, Okayama, Japan).
HOXB7 overexpression by lentiviral vectors. The ampli-
fied HOXB7 complementary DNA sequence was cloned into
the pWPI lentiviral vector (kindly provided by Dr Trono,
National Center for Competence in Research, Switzerland).
Recombinant lentivirus was produced by transient transfection
of 293T cells following standard protocol.24 The transduction
efficiency of JJN3 was evaluated by green fluorescence protein
expression using flow cytometry whereas the efficacy assessed
by the evaluation of HOXB7 messenger RNA (mRNA) and
protein expression.
Small interfering RNA (siRNA) transfection. The KMS20
cells were mixed either with 2 nmol of siRNA against HOXB7
(siHOXB7) or with a non-specific control siRNA (siuntarg,
Dharmacon Tech, Lafayette, CO, USA) and electroporated using
the Gene Pulser electroporation apparatus (Bio-Rad Laboratories
Inc., Hercules, CA, USA) following a single-pulse protocol.
24–48 h (h) after siRNA transfection, cellular pellets were
obtained for mRNA and protein extraction and conditioned
media stored at 20 1C for further analysis.
Cell proliferation and viability. Measurement of cell
viability and DNA synthesis was performed by MTT cell
proliferation assay (Cayman Chemical, Ann Arbor, MI, USA)
and by tritiated thymidine (Biocompare, South San Francisco,
CA, USA) uptake in 96-well microtiter plates, respectively.
Angiogenesis in vitro and ex vivo assays
In vitro angiogenesis assay. Angio-kit was used to test the
in vitro pro-angiogenic properties of the samples, according to
the manufacturer’s protocol (TCS Biologicals Buckingham, UK).
Briefly, endothelial-like cells were stimulated with VEGF
(2 ng/ml, positive control) or suramin (20 mM, negative control),
or conditioned medium (CM) of JJN3 cells infected with pWPI
empty vector (JJN3-pWPI) or HOXB7 vector (JJN3-HOXB7)/
D-MEM at 10% fetal bovine serum (ratio 1:3), or with CM of
KMS20 untarg, or KMS20 siHOXB7/D-MEM at 10% fetal bovine
serum (ratio 1:3). At day 11, the cells were fixed and stained
using an anti-hCD31 Ab and capillaries formation measured
according to the instructions provided (TCS Biologicals).
Chorioallantoic membrane (CAM) assay. Fertilized
White Leghorn chicken eggs (20 per group) were treated with:
1 mm3 sterilized gelatin sponges (Gelfoam Upjohn, Kalamazoo,
MI, USA) placed on top of the growing CAM, as previously
described25 and loaded with 1 ml of phosphate-buffered saline
(negative control); 1ml of phosphate-buffered saline with 250 ng
VEGF (R&D Systems, Minneapolis, MN, USA) as positive
control; 1ml of CM of JJN3-pWPI 1ml of CM of JJN3-HOXB7.
The supernatants were tested in triplicate.
Mice study
SCID-NOD mice aged 4–6 weeks (Harlan Laboratories, Udine,
Italy) were housed under specific pathogen-free conditions.
All procedures involving animals were performed in the respect
of the National and International current regulations (D.l.vo
116/1992, European Economic Community Council Directive
86/609, OJL 358, 1987). Two groups of 10 animals each were
injected sub-cutaneously with 5 106 JJN3 cells stably infected
with a lentivirus vector carrying HOXB7 (JJN3-HOXB7), or
with JJN3 stably infected with an empty vector (JJN3-pWPI). At
23 days after tumor cell inoculation, mice were killed and
autopsies were carried out. Tumoral masses were measured
as previously described.26 Maximum length and width of the
tumoral masses were measured with a caliper, and tumor
volume (mm3) was calculated according to the following
formula: 0.523 lengthwidth2. Tissue samples and cell
extracts of the masses were obtained for immunohistochemical
staining and for RNA and protein extraction, respectively.
Gene expression profiling analysis
The gene expression profile of HOXB7 was evaluated in the
proprietary databases of highly purified CD138þ PC samples
from four healthy donors, 11 MGUS, 133 MM, 9 PC leukemia
and 23 HMCLs samples profiled on the GeneChip HG-U133A
arrays (Affymetrix, Santa Clara, CA, USA) as previously
described.27,28 The CEL files are deposited at the National
Center for Biotechnology Information’s Gene Expression Omni-
bus and available through GEO Series accession numbers
GSE1359127 and GSE6205.28
The transcriptional profiles of samples from infected HMCLs
and tumoral masses in mice were generated on GeneChip HG-
U133 Plus 2.0 arrays according to the standard manufacturer’s
preparation and hybridization protocols. Data were extracted
from CEL files and converted to normalized signals using
conventional GCOS1.1 scaling. The differential expression of
transcripts was tested using Significant Analysis of Microarrays
software version 3.0.2 as previously described.28 NetAffx
(https://www.affymetrix.com/analysis/netaffx/), DAVID 2008
(http://david.abcc.ncifcrf.gov) and Gene Set Enrichment Analy-
sis (GSEA, http://www.broad.mit.edu/gsea) tools were used for
the functional annotation study of the selected lists.
RNA isolation and reverse transcriptase PCR
amplification
For reverse transcriptase PCR analysis, total cellular RNA was
extracted from cells using RNeasy mini kit (Qiagen, Milan,
Italy). A volume of 1mg of RNA was reverse-transcribed using
the Superscript RnaseH-reverse trascriptase kit according to
the manufacturer’s protocol (Invitrogen, Milan, Italy).
Complementary DNAs were amplified by PCR with specific
primer pairs. PCR reactions were performed in a thermal cycler
(MiniCycler MyResearch, Watertown, MA, USA) for 30 cycles.
The following specific primer pairs have been used:
 HOXB7: F: 50-AGAGTAACTTCCGGATCTA-30; R: 50-TCTGC
TTCAGCCCTGTCTT-30
 VEGFA: F: 50-CGAAGTGGTGAAGTTCATGGATG-30; R: 50-T
TCTGTTCAGTCTTTCCTGGTGAG-30
 FGF2: F: 50-GGCTTCTTCCTGCGCATCCAC-30; R:30-GGTAA
CGGTTAGCACACTCCTTT-30
 MMP2: F: 50-TGGGCAACAAATATGAGAGAG-30; R:50-CGG
CATCCAGGTTATCGGGG-30
 PDGFA: F: 50-CCCCTGCCCATTCGGAGGAAGAGA-30;
R: 50-TTGGCCACCTTGACGCTGCGGTG-30
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 TSP2: F: 50-GCAACATCAACCGCAAGAC-30; R: 50-AAGCA
AACCCCTGAAGTGACT-30
 WNT5a: F: 50-GAGTTCGTGGACGCCCGCGA-30; R:50-GGC
TCATGGCGTTCACCAC-30
 GAPDH: F: 50-CAACGGATTTGGTCGTATTG-30; R:50-GGA
AGATGGTGATGGGATTT-30
Annealing temperature. HOXB7: 58 1C; VEGFA: 56 1C;
FGF2: 57 1C; MMP2: 55 1C; PDGFA: 56 1C; thrombospoindin-2
(TSP2): 59 1C; WNT5a: 69 1C; GAPDH: 58 1C.
Product size. HOXB7: 274bp; VEGFA: 375 bp; FGF2: 136
bp; MMP2: 750 bp; PDGFA: 228bp; TSP2: 541 bp; WNT5a: bp;
GAPDH: 209 bp.
Pictures of the electrophoresed complementary DNAs were
recorded with a digital DC 120 Kodak camera and quantified.
Real time quantitative PCR and angiogenesis PCR array
Real time PCR was performed by adding 2 out of 20ml of
complementary DNA, obtained from 1 mg of RNA, to an
universal master Mix primers and TaqMan probes (Applied
Biosystem, Applera, Milan, Italy).
The following TaqMan Gene Expression Assays were
used: Hs00270131_m1 (HOXB7), Hs00173626_m1 (VEGFA),
Hs00266645_m1 (FGF2), Hs00167093_m1 (OPN), Hs00998537_m1
(WNT5a) and Hs01104728_m1 (ABL) according to the manu-
facturer’s protocols. For IL8 and ANG1 the sequences of the
primers and probes used were as follows:
 IL8: F: 50-CTCTTGGCAGCCTTCCTGATT-30; R: 50-TATGCAC
TGACATCTAAGTTCTTTAGCA-30; probe: 6-FAM-CTTGGCA
AAACTGCACCTTCACACAGA-MGB
 ANG1: F: 50-GCAACTGGAGCTGATGGACACA-30; R: 50-CA
TCTGCACAGTCTCTAAATGGT-30; probe: 6-FAM-CAATCTT
TGCACTAAAGAAGGTGTTTTACT-MGB
To normalize for differences in RNA quality and reverse
transcription efficiency, we applied the comparative Ct method
using the endogenous reference gene ABL. The relative HOXB7
mRNA quantification was performed by the DCt method
(DCt¼meanCT HOXB7meanCT ABL). DDCt was evaluated as
the difference between the DCt of a sample and the DCt of the
control. The fold change in HOXB7 mRNA expression (n-fold)
was calculated as 2DDCt. The same procedures were used for
the other genes analyzed.
The expression level of the pro-angiogenic molecules was
evaluated on mRNA extracted from both HMCLs and tumors
removed from SCID-NOD mice by Human Angiogenesis RT2
Profiler PCR Array and RT2 Real-Timer SyBR Green/ROX PCR
Mix (PAHS-024, Superarray, SABiosciences, Frederick, MD) that
profiles the expression of 84 key genes involved in modulating
the biological processes of angiogenesis.
Western blot analysis and angiogenesis antibody array
Nuclear extracts were prepared using the Nuclear Extraction kit
(Active Motive, Vinci Biochem, Italy) according to the manu-
facturer’s protocol. A volume of 40mg of nuclear extracts and
70mg of cytosolic extracts were electrotransferred onto PVDF filters
(Bio-Rad Laboratories S.r.l. Segrate (MI), Italy) after sodium dodecyl
sulphate polyacrylamide gel electrophoresis. After blocking, filters
were probed with specific antibodies overnight at 4 1C. The
following antibodies were used as primary Abs: polyclonal rabbit
anti-HOXB7 Ab. (Zymed Laboratories, Invitrogen; dilution: 1:125),
polyclonal goat anti-bFGF Ab. (R&D Systems; dilution: 1:250),
anti-VEGF monoclonal Ab (R&D; dilution: 1:250) and anti-HIF-1a
(R&D; dilution 1:250). Anti-histone H1 monoclonal Ab (Millipore,
Billerica, MA, USA; dilution 1:500) and anti-bactin monoclo-
nalAb (Sigma-Aldrich, Milan, Italy; dilution: 1:5000) were used
as internal controls. Appropriate secondary antibodies were
used as peroxidase conjugated anti-rabbit (Chemicon, Millipore,
Billerica, MA, USA), anti-goat (Rockland, Gilbertsville, PA,
USA) or anti-mouse immunoglobulin (BD Pharmingen, Franklin
Lakes, NJ, USA). Blots were then developed using the ECLplus
(Amersham International plc, Buckinghamshire, UK). Immuno-
reactive bands were visualized by a 5–15 min exposure (Kodak
X-OMAT, Milan, Italy).
The expression profile of angiogenesis-related proteins was
analyzed by both human angiogenesis array kit (ARY007, R&D
Systems) and Quantibody angiogenesis array (RayBiotech Inc.
Norcross GA, USA) according to the manufacturer’s protocols.
The intensity of each band was quantified by ID Image Analysis
Software (Kodak).
Enzyme-linked immunosorbent assay assays
Aliquots of 48-h cell CM were tested for soluble VEGF, PDGFA,
MMP-2 and TSP2 (R&D Systems) protein levels according
to the manufacturer’s protocols. Cytokine levels in the CM
were normalized to the total protein levels at the end of
culture period.
BM angiogenesis and immunohistochemical staining of
VEGF, bFGF, CD31 and Ki-67
BM angiogenesis was evaluated on bone biopsies of the 22 MM
patients analyzed as previously described.13,14 Angiogenesis
was measured as density of microvessels by staining endothelial
cells using anti-CD34 monoclonal Ab (working dilution 1:50,
clone QBEnd/10 NeoMarkers, Fremont, CA, USA). The mean of
vascular density and the mean number of microvessels in each
biopsy were expressed on the basis of total number of
microvessel transversal section (capillaries and/or venules) per
the total cellular area (in mm2) and per the total number of fields
( 400 magnification), respectively.13,14
Tissue samples obtained from tumors removed from SCID-
NOD mice colonized by JJN3-pWPI and JJN3-HOXB7 (10
mouse for each group) were fixed in 10% neutral-buffered
formalin, embedded in paraffin, sectioned at 3 mm, and stained
with hematoxylin and eosin. In addition, fixed sections were
immuno-stained with mouse anti-human VEGF (R&D; dilution
1:20) or biotinylated goat anti-human bFGF (R&D; dilution 1:20)
or with 1:100 diluted mouse anti-Ki67 primary antibody (Clone
MIB-1, Dako, Carpinteria, CA, USA) for 30 min. VEGF staining
was revealed using the UltraVision LP Large Volume Detection
System horseradish peroxidase polymer (Thermo Scientific)
whereas bFGF staining by horseradish peroxidase-labeled
streptavidin (Kit LSAB2, DakoCytomation Denmark, Glostrup,
Denmark) and quantified according to semiquantitative immu-
nohistochemical score.13 Detection of Ki-67 has been carried
out using high-sensitive detection system (Advance-horseradish
peroxidase, Dako) and 3,3-diaminobenzidine has been emp-
loyed as chromogen substrate. Angiogenesis was evaluated on
frozen tissues samples obtained from SCID-NOD mice fixed in
acetone and treated with rabbit anti-mouse CD31/PECAM-1
(Millipore; 1:1000). After washing sections were incubated
with a secondary antibody (Rat anti-IgG horseradish peroxidase;
Millipore; 1:250) and reaction revealed with a solution of
3-30-diaminobenzidine tetrahydrochloride (liquid DAB substrate
chromogen system, DAKO). Slides were then incubated.
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HOXB7 expression characterizes a fraction of MM
primary tumors: relationship with BM angiogenesis
HOXB7 mRNA expression in a proprietary microarray database
of highly purified PC from MM primary tumors was first
analyzed (Figure 1a). To investigate whether HOXB7 differential
expression could be associated with distinct transcriptional
profiles, the MM cases, based on HOXB7 expression, were
ordered and divided into four quartiles. The supervised analy-
sis led to the identification of 168 genes (at a q-value¼ 0), 91
of which upregulated in the fourth quartile (Supplementary
Figure 1). Interestingly, among them, we identified both the
pro-angiogenic genes MMP2 and PDGFA.
HOXB7 mRNA expression was then evaluated in freshly
isolated CD138þ MM cells obtained from 22 MM patients at the
diagnosis. The presence of HOXB7 mRNA transcript was
observed in 10 out of 22 CD138þ MM PC analyzed but not
in the PC from tonsils or BM of healthy individuals (Table 1).
Interestingly, we found that BM angiogenesis was significant
higher in patients positive for HOXB7 mRNA as compared
with those negative for HOXB7 mRNA (number of microvessels
per field: mean±s.e.: 8.54±0.31 vs 5.78±0.2, median: 8.05 vs
5.2; P¼ 0.03 and MVD: mean±s.e.: 37.6±1.83 vs 16.05±0.6,
median: 34.6 vs 14.5; P¼ 0.005). HOXB7 protein expression
was also evaluated and detected at nuclear level in 5 out of 16
MM patients available but not in CD138þ PC from healthy
donor (data not shown).
Figure 1 HOXB7 expression by MM cells. Distribution of HOXB7 expression level profiled on HG-U133A arrays in 133 MM samples, 4 normal
(N) plasma cells (PC), 11 MGUS and 9 plasma cell leukemia PCL (a) and in human myeloma cell lines (HMCLs) (b). Graphs represent the absolute
gene expression level of the specific probset GC17M044039_at. *Indicates HMCLs with HOXB7 expression level more than three standard
deviations as compared with BM PCs from healthy subjects. Box plot of HOXB7 mRNA gene expression levels in 4 normal plasmacells (nPC)
and 23 HMCLs (b on the left). Box blots of HOXB7 mRNA level in 4 nPC, 20 MM and 5 HMCLs quantified by real time PCR (c). HOXB7
mRNA expression by HMCLs (JJN3, RPMI-8226, KMS12, KMS20 and KMS27) and normal plasma cells (nPC) was evaluated using qualitative
PCR (d). HOXB7 protein expression was detected in HMCLs at nuclear level by westernblot analysis. (Conþ , positive controlFHOXB7-
transduced cells) (e).
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HOXB7 is overexpressed by HMCLs
Thereafter, HOXB7 mRNA expression was analyzed in a
proprietary microarray database including 23 HMCLs finding
that 10 (43%) of them overexpressed HOXB7 in comparison
with CD138þ samples from healthy donors (Figure 1b). Based
on microarray dataset, HOXB7 mRNA expression was analyzed
in a subgroup of HMCLs by both quantitative and qualitative
PCR. We confirmed that HOXB7 mRNA level was significantly
higher in HMCLs as compared with normal CD138þ PC
whereas the difference between HMCLs and CD138þ MM
cells did not reach a statistical significance as well as between
normal PC and CD138þ MM cells (Figure 1c). Moreover,
among the HMCLs analyzed, we found that RPMI-8266,
KMS12, KMS20 and KMS27 expressed HOXB7 mRNA tran-
script, whereas JJN3 was negative as well as normal CD138þ
PC (Figure 1d). Data were then confirmed at protein level
finding that RPMI-8226, KMS12, KMS20 and KMS27 show a
constitutive HOXB7 expression at nuclear level, whereas JJN3
did not express HOXB7 (Figure 1e).
Effect of HOXB7 overexpression on whole
transcriptional and angiogenic profiles of MM cells:
upregulation of pro-angiogenic molecules
In order to investigate the potential role of HOXB7 on the whole
transcriptional and specifically pro-angiogenic profile of MM
cells, first we enforced HOXB7 expression by a lentiviral vector
in JJN3 cells (JJN3-HOXB7) that do not constitutively express
HOXB7. The efficiency of HOXB7 transduction was more that
95% as assessed by green fluorescence protein evaluation by
flow cytometry (Figure 2a). Consequently, the efficacy of
lentiviral transduction was demonstrated by the significant
increase of HOXB7 mRNA level (median fold change: 450) in
JJN3-HOXB7 as compared with JJN3 transduced with the empty
vector (JJN3-pWPI) and confirmed by qualitative PCR and at
protein level by western blot (Figure 2a, left and middle panel).
A slight stimulatory effect on cell proliferation was observed in
JJN3-HOXB7 in comparison with JJN3-pWPI (data not shown).
First, the effect of HOXB7 overexpression on the main pro-
angiogenic molecule production by MM cells was evaluated. By
real time PCR, using the TaqMan Gene Expression Assays, we
found that VEGFA and FGF2 were significantly upregulated
(P¼ 0.001 and P¼ 0.01, respectively) but not OPN, IL8 and
ANG1 (Figure 2b). Second, by means of a gene-expression
profiling study on JJN3 triplicates we found that 756 genes were
significantly modulated by HOXB7 overexpression including
chemokine and chemokine receptor genes as CCL3, CCL5,
CXCL1 and CCR1; genes belonging to cell adhesion molecule
family as SDC1 (syndecan1), CDH1 (E-Cadherin), CDH2
(N-Cadherin), CDH11, NCAM1 and CD28 and genes belonging
to Janus Kinase (JAK)-Signal Transducer and Activator of Trans-
cription (STAT) and p53 signaling pathways (Supplementary
Table 1). Particularly, among the pro-angiogenic genes we
found the significant upregulation of VEGFA, MMP2, WNT5A,
PDGFA and the specific downregulation of the MMP inhibitor
TIMP2 (Table 2 (i) and Supplementary Table 1). These data were
in accordance with those observed in primary MM tumors, being
the large part of these genes identified at a q-valueo0.03 in the
previously described supervised analysis. These data were then
validated and integrated by PCR (Figures 2c and d, respectively) for
VEGFA, FGF2, MMP2 and PDGFA. Interestingly, using angiogenesis
PCR arrays we also found that the angiogenic inhibitor TSP2 was
significantly inhibited. Data were confirmed at protein level by
western blot for bFGF (Figure 2e) and enzyme-linked immuno-
sorbent assay for VEGF, MMP-2, PDGF and TSP2 (Figure 2f).
HOXB7 silencing inhibited the production of
pro-angiogenic molecules by MM cells
To further evaluate the potential role of HOXB7 in the
production of angiogenic molecules by MM cells we performed
HOXB7 silencing by siRNA in the KMS20 HMCL that
Table 1 HOXB7 mRNA expression and BM angiogenesis in MM patients
Samples ISS Type HOXB7 mRNA BM MVD BM no. of vessels
Healthy tonsil CD138+ / /  / /
Healthy tonsil CD138+ / /  / /
Healthy tonsil CD138+ / /  / /
Healthy tonsil CD138+ / /  / /
Healthy BM CD138+ / /  / /
MM1 I k + 25.75 8.08
MM2 III k + 16.52 5.78
MM3 I k  17.93 10.5
MM4 III l  41.73 9.56
MM5 III k  29.92 6.06
MM6 III l + 21.18 5.57
MM7 III k + 63.01 14.61
MM8 III k + 34.66 8.05
MM9 III k + 35.74 7.96
MM10 III k  17.4 3.0
MM11 III l  49.17 8.06
MM12 II k  12.8 5.40
MM13 I l  30.89 7.13
MM14 I l  14.9 3.49
MM15 II k  14.2 2.94
MM16 I k + 63.54 7.69
MM17 I k  9.58 3.59
MM18 I l  16.38 5.15
MM19 II l + 50.99 12.47
MM20 II k  11.67 4.53
MM21 I l + 34.69 6.11
MM22 II k + 30.99 9.08
MVD, microvascular density; no. of vessels, total number of vessels for field.
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constitutively expresses HOXB7. A significant reduction of
HOXB7 transcript level was obtained by siRNA transfection
after 24 h (fold change of reduction: KMS20 siHOXB7 vs KMS20
siuntarg: 0.13), confirmed by qualitative PCR (Figure 3a), as
well as a dowregulation of its nuclear protein level after 48 h
(Figure 3a). A slight reduction on cell viability and proliferation
was observed in KMS20 transfected with siHOXB7 as compared
with siuntarg (data not shown). HOXB7 silencing significantly
reduced VEGF, FGF2 and TGFB1 mRNA level (Figure 3b),
whereas any significant effect was not observed on the other
angiogenic molecules (data not shown). Data were then
validated by qualitative PCR (Figure 3c) as well as by
angiogenesis antibody array showing a significant reduction of
VEGF, bFGF and TGFb protein levels in KMS20 siHOXB7 as
compared with KMS20 siuntarg (Figure 3d).
HOXB7 involvement in the pro-angiogenic effect of
MM cells
Given that HOXB7 regulates the expression of the pro-angio-
genic molecules in HMCLs, the role of HOXB7 modulation
on MM-induced endothelial-cell proliferation and survival was
Figure 2 Effect of HOXB7 overexpression in MM cells: upregulation of the pro-angiogenic molecules. JJN3 was infected either with HOXB7
lentivirus vector (JJN3-HOXB7) or the empty vector (JJN3-pWPI). The efficiency of the transduction was evaluated by GFP evaluation using flow
cytometry, whereas the efficacy was assessed evaluating HOXB7 expression by qualitative PCR and western blot (a). The expression of VEGFA,
FGF2, OPN, IL-8 and ANG1 was evaluated at mRNA level by real time PCR by TaqMan Gene Expression Assays in transduced cells. Graphs
represent the median mRNA fold expression value (2(DCt JJN3-HOXB7  DCt JJN3)) in JJN3-HOXB7 vs JJN3-pWPI assessed in triplicate (b).
By angiogenesis PCR array using the Real-Timer SyBR Green/ROX PCR Mix, the pro-angiogenic and anti-angiogenic genes were assessed in
JJN3-HOXB7 as compared with JJN3-pWPI. Graphs represent the median mRNA fold change of the genes significantly modulated according to the
manufacturer’s protocol (c). The expression of VEGFA, FGF2, MMP2, PDGFA and TSP2 mRNA was evaluated by qualitative PCR in JJN3-HOXB7
and JJN3-pWPI (d). bFGF protein expression was evaluated by western blot analysis in JJN3-HOXB7 and JJN3-pWPI. rhbFGF has been used as
positive control (Con þ ) (e). Aliquots of CM of JJN3-HOXB7 and JJN3-pWPI were tested for VEGF, MMP-2, PDGF, TSP-2 protein levels by ELISA
assay. Graphs and bars represent the mean protein values±s.d. of three independent experiments performed twice (f).
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Table 2 Angiogenesis-related genes significantly modulated by HOXB7 overexpression in JJN3 (i) and in JJN3-HOXB7 tumoral mass in mice (ii)
Gene name Gene symbol Probe set Fold change
(i)
Homeobox B7 HOXB7 204778_x_at 7.95
Matrix metallopeptidase 2 MMP2 201069_at 15.85
Chemokine (C-C motif) ligand 5 CCL5 1405_i_at 15.39
Wingless-type MMTV integration site family, member 5A WNT5A 213425_at 13.73
Platelet-derived growth factor alpha polypeptide PDGFA 205463_s_at 13.38
Vascular endothelial growth factor A VEGFA 212171_x_at 5.88
TIMP metallopeptidase inhibitor 2 TIMP2 231579_s_at 2.20
(ii)
Homeobox B7 HOXB7 204778_x_at 4.27
Fibroblast growth factor receptor 3 FGFR3 204379_s_at 31.38
Chemokine (C-C motif) ligand 5 CCL5 1405_i_at 6.71
Platelet-derived growth factor alpha polypeptide PDGFA 205463_s_at 4.44
Wingless-type MMTV integration site family, member 5A WNT5A 213425_at 3.86
Transforming growth factor, beta-induced 68 kDa TGFB1 201506_at 2.29
Placental growth factor-2 PGF 215179_x_at 2.08
Vascular endothelial growth factor A VEGFA 212171_x_at 2.0
TIMP metallopeptidase inhibitor 2 TIMP2 231579_s_at 2.0
Figure 3 Effect of HOXB7 silencing in MM cells: downregulation of pro-angiogenic molecules. KMS20 were transfected by electroporation with
siRNA against HOXB7 (KMS20 siHOXB7) or with a non-specific control siRNA (KMS20 siuntarg). HOXB7 mRNA and protein expression was
evaluated by RT–PCR and by westernblot analysis on nuclear extracts (Conþ , positive controlFJJN3-HOXB7-transduced cells), respectively (a).
Angiogenic genes significantly modulated were assessed in KMS20 siHOXB7 as compared with KMS20 siuntarg by angiogenesis PCR array.
Graphs represent the median mRNA fold change of VEGFA, FGF2 and TGFb1 (b). mRNA expression of these molecules was evaluated by
qualitative PCR in KMS20 siHOXB7 and KMS20 siuntarg (c). Graphs and bars represent the mean %±s.d. of protein level change of VEGF, FGF2
and TGFb in siHOXB7 as compared with KMS20 siuntarg cells checked by angiogenesis antibody array (d).
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then tested using two different angiogenesis assays as Angiokit
and CAM assays. First, we found that CM of JJN3-HOXB7
significantly stimulated vessel formation as compared with JJN3-
pWPI (JJN3-HOXB7 vs JJN3-pWPI: number of capillar junctions:
mean±s.d.: 18.5±1.9 vs 10±1, P¼ 0.01; number of tubules:
76.5±4 vs 55±3.9, Po0.01; tubule length: 2542±108 mm vs
1836±150 mm, Po0.01) (Figure 4a). VEGF treatment was used
as positive control of the system. (VEGF vs vehicle (Con):
number of capillary junctions: 22±0.8 vs 6±1.12, P¼ 0.001;
number of tubules: 90.2±1.17 vs 40±3.9, P¼ 0.001; tubule
length: 3000±78 mm vs 1036±150 mm, P¼ 0.001).
This observation was confirmed in the CAM assay finding that
the angiogenic response induced by the JJN3-HOXB7 was
significantly higher as compared with JJN3-pWPI (mean
number of vessels¼ 20±4 vs 2±2, Po0.001; VEGF¼ 24±4;
Con¼ 7±2) (Figure 4b).
Second, to demonstrate unambiguously that HOXB7 is a key
molecule in the regulation of the angiogenic properties of MM
cells, we tested the effect of HOXB7 silencing on the angiogenic
response of MM cells by the Angiokit. We found that CM of
KMS20 siHOXB7 induced a significantly lower pro-angiogenic
effect as compared with KMS20 siuntarg. (capillary junctions:
11±0.96 vs 21±0.8; tubules: 50.75±1.23 vs 85.5±4.6; tubule
length: 1862±57.78 mm vs 2833±122 mm, Po0.01) (Figure 4a).
HOXB7 overexpression stimulated MM-induced
angiogenesis in vivo in SCID-NOD mice
Next, the effect of HOXB7 overexpression by MM cells was
investigated in vivo in SCID-NOD mice. Two groups of ten
animals were injected sub-cutaneously with JJN3-HOXB7 or
JJN3-pWPI and killed after 23 days. By the end of the follow-up
period, all mice developed tumors that grew in the site of
injection, in the absence of metastases at distant sites. Mice
injected with the JJN3-HOXB7 cells developed tumors signifi-
cantly bigger than mice inoculated with the JJN3-pWPI (JJN3-
HOXB7 tumors, mean volume 214 mm3; range 142–2063 mm3;
JJN3-pWPI tumors, mean volume 134 mm3; range 3–718 mm3,
P¼ 0.0039) (Figure 5a). However, we failed to find a significant
difference in Ki-67 immunohistochemical staining in the two
groups of tumors analyzed (data not shown). Histological
samples were then both frozen and paraffin-embedded to stain
CD31 and VEGF. We found that the number of vessels for field
(400) positive for CD31 was significantly higher in JJN3-
HOXB7 tumoral masses as compared with JJN3-pWPI (median
value: 4.50 vs 3.20; P¼ 0.05) (Figure 5b panel i). Consistently
we found that VEGF immunostaining was at higher intensity in
JJN3-HOXB7 tumoral masses (immunohistochemical score:
þþ /þþþ ) vs JJN3-pWPI (/þ ) (Figure 5b panel ii).
The overexpression of HOXB7 in JJN3-HOXB7 tumoral
masses as compared with JJN3-pWPI was checked by real time
PCR (HOXB7 vs pWPI 2DDCT: 500) and by western blot (data
not shown). Following, in order to investigate whether HOXB7
overxpression may also affect in vivo the transcriptional (and
specifically the pro-angiogenic) profile of MM, we performed
microarray analysis on cellular pellets from both JJN3-HOXB7
and JJN3-pWPI tumoral masses. The supervised analysis
revealed 631 differentially expressed genes including genes
belonging to cell adhesion molecules and focal adhesion factors
as CDH2, NCAM, CD28, CTNNB1 (beta-catenin) and CCL3
(Supplementary Table 2) or to angiogenesis as VEGFA, PGF,
PDGFA, WNT5A, TGFB1, CCL5, TIMP2 and FGFR3 (Table 2 (ii)
and Supplementary Table 2). Data obtained by microarrays
were then validated by real time PCR on selected genes (HOXB7
vs pWPI 2DDCT for VEGFA: 8.2; FGF2: 3.2; WNT5a: 5.0) and
integrated by angiogenesis PCR array showing the upregulation
of VEGFA, VEGFC, PGF, FGF2, FGFR3, MMP2, PDGFA and
CD31 mRNA expression levels and the decrease of TSP2
(Figure 5c) in JJN3-HOXB7 tumoral masses as compared with
JJN3-pWPI. Finally, by angiogenesis antibody array a significant
upregulation of VEGF, bFGF and PDGFA at protein levels in JJN3-
HOXB7 as compared with JJN3-pWPI (Figure 5d) was found.
Validation on MM primary tumor dataset of HOXB7-
related angiogenic molecules
Finally, we attempted to validate the pro-angiogenic and anti-
angiogenic genes (VEGFA, WNT5A, MMP2, PDGFA, TGFB1,
Figure 4 HOXB7 overexpression by MM cells increases their
pro-angiogenic properties. Endothelial-like cells were incubated with
DMEM medium at 10% FBS (Con) or with DMEM medium at 10% FBS
plus VEGF or with CM of JJN3-pWPI or JJN3-HOXB7/D-MEM at 10%
FBS or KMS20 siuntarg or KMS20 siHOXB7 (dilution 1:3). (Original
magnification  10) (a). Fertilized white leghorn chicken eggs were
treated with 1 mm3 sterilized gelatin sponges placed on top of the
growing CAMs and loaded with 1 ml of CM of JJN3-pWPI or 1ml of CM
of JJN3-HOXB7. CAMs were photographed with a camera and image
analyzer system (Olympus Italia, Italy) (b).
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TSP2, TIMP2 and FGF2) found to be significantly associated
to HOXB7 modulation in HMCLs both in vitro and in vivo.
Specifically, using a classification approach on the large
GSE2658-independent datasets28 of primary MM tumors, we
evaluated whether the combination, in whole or in part, of such
genes could distinguish the samples showing lower and higher
HOXB7 expression. The most powerful combination was
represented by VEGFA, WNT5A, TGFB1, TIMP2 and FGF2,
which correctly classified 62% of the 280 samples, included in
the first and fourth HOXB7 expression-based quartiles (Supple-
mentary Table 3).
Discussion
HOXB7 is a homeobox-containing transcription factor mediating
several developmental process including hemopoietic differentia-
tion and lymphoid development as well as leukemogenesis.29,30
HOXB7 overexpression has been previously reported in solid
tumors as breast,20,21 melanoma22,31 and ovarian cancers32
in relationship with tumor cell-invasion ability, metastasis
and angiogenesis suggesting the potential role of this gene in
tumoral progression.18,21,22,32 Among hematological malig-
nancy HOXB7 overexpression has been recently reported in
chronic lymphocytic leukemia samples as compared with B
and T lymphocytes.33 In the present study, analyzing HOXB7
gene profile in primary MM cells, we show that HOXB7 is
overexpressed by more than 40% of HMCLs and a fraction of
MM patients at the diagnosis related to BM angiogenesis.
Recently, in-line with our observation an overexpression of
HOXB7 has been reported in extramedullary MM as compared
with intramedullary cases.34
Then we focalized our attention on the potential involvement
of HOXB7 in the production of pro-angiogenic molecules by
MM cells and their pro-angiogenic properties in order to clarify
the molecular mechanisms underling MM-induced angiogenic
Figure 5 Effect of HOXB7 overexpression by MM on pro-angiogenic factors in vivo in SCID-NOD mice. Two groups of SCID-NOD mice each
were injected sub-cutaneously with 5 106 JJN3-HOXB7 or with JJN3 JJN3-pWPI. Box blots represent the median tumoral mass volume of JJN3-
HOXB7 and JJN3-pWPI colonized mice (a). CD31 and VEGF immunostaining was performed on frozen tissues (b panel i) and on formalin-fixed
paraffin embedded sections (b panel ii), respectively, (original magnification  100). Graphs represent the median mRNA fold change of the
angiogenic genes significantly modulated in JJN3-HOXB7 tumoral masses as compared with JJN3-pWPI performed in triplicate by angiogenesis
PCR array (c). VEGF, bFGF and PDGFA protein expression was assessed in cell lysates obtained from tumoral masses by angiogenesis antibody
array. Graphs represent the mean %±s.d. of protein level change JJN3-HOXB7 tumoral masses as compared with JJN3-pWPI performed twice (d).
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switch. Two different approaches were used to investigate the
pro-angiogenic role of HOXB7, either by enforcing HOXB7
expression by lentivirus vectors in JJN3 or silencing its constitutive
expression in KMS20 by appropriate siRNA. Thus, we evaluated
the potential effect on the transcriptional and angiogenic profile of
MM cells using combined gene-expression profiling analysis and
PCR angiogenesis arrays demonstrating that HOXB7 overexpres-
sion increased VEGFA, FGF2, MMP2 and PDGFA gene expression
and the corresponding proteins. Among these factors, VEGF, bFGF
and MMP-2 are well known pro-angiogenic factors produced by
MM cells1,9–11,15,16 and critically involved in the angiogenic
process, whereas the role of PDGFA in MM cells is not known
even if its pro-angiogenic activity in cancer cells is well
established.35 In-line with our results it has been previously
reported that HOXB7 overexpression regulates bFGF in breast and
melanoma cancer cells19,22 as well as VEGF.18 On the contrary we
failed to observe a modulation of Ang-2 and IL-8 by HOXB7
overexpression as reported by others.18 Interestingly, other than the
induction of pro-angiogenic molecules we found that HOXB7
overexpression inhibited the production of anti-angiogenic factors,
particularly thrombospondin-2, which is known to act as a potent
inhibitor of tumoral angiogenesis36 and is deregulated in MM
patients.37 The capacity of HOXB7 to modulate the production of
the pro-angiogenic factors by MM cells was confirmed by silencing
HOXB7 in KMS20, that significantly inhibited the expression of
VEGF and bFGF. TGFb was also inhibited by HOXB7 down-
regulation in KMS20, as well as several genes belonging to TGFb
signal pathway, including BMP2 and BMP7 were regulated by
HOXB7 overexpression in JJN3. Furthermore, the correlation
among HOXB7 overexpression and the modulation of pro-
angiogenic factors was observed in large datasets of proprietary
and publicly available primary tumors, with the additional
validation given by the good prediction capacity of five genes
(VEGFA, WNT5A, TGFB1, TIMP2 and FGF2) to classify a consis-
tent number of independent samples from GSE2658 series. This
suggests that the association between HOXB7 upregulation and
higher expression of pro-angiogenic factors is a conserved
characteristic of MM disease, and is not affected by lab- or
cohort-specific biases.
Consistently with the role of HOXB7 in the production of
pro-angiogenic molecules by MM cells, we found that their
angiogenic properties were significantly regulated by HOXB7
modulation in two different widely used and validated in vitro
and ex vivo angiogenic models.1,13,14,25 Finally, to confirm
the pathophysiological role of HOXB7 in MM-induced angio-
genesis, we tested the effect of its overexpression in MM cells
using a SCID-NOD mice model previously tested.38 Interest-
ingly, together with higher MM-associated angiogenesis and
VEGF expression we found that the tumor burden was signi-
ficantly higher in JJN3-HOXB7 injected mice as compared with
JJN3-pWPI suggesting that the increased vessel formation might
stimulate MM growth. However, we can also suppose that
HOXB7 directly affects MM cell growth given that its over-
expression stimulated JJN3 proliferation rate as well as HOXB7
silencing inhibited cell proliferation and survival in KMS20.
Accordingly, it has been previously reported that HOXB7
expression regulates cell proliferation in breast cancer21 and
myeloid progenitor cells.30 The role of HOXB7 in the regulation
of the pro-angiogenic profile of MM cells was then further
confirmed by combined microarray analysis and angiogenesis
PCR arrays in tumoral masses obtained from mice. Interestingly,
among the genes significantly modulated by HOXB7 over-
expression, we found WNT5a upregulation. WNT5a is an acti-
vator of non-Wnt canonical pathway transduced through FZD
and Ror2 co-receptors to several cascades, either disheveled
pathways involving Rho family small GTPase and JNK or Caþþ
dependent pathways.39 Consistently to our data, it has been
previously shown that HOXB7 overexpression by breast-cancer
cells induced Rho and Ras GTP-ase activation and consequently
cell migration and invasion.20 Recent evidences also indicate
that WNT5a signaling stimulates endothelial cell proliferation
and survival showing a pro-angiogenic effect.40 In addition, it
has been demonstrated that WNT5a expression could be
associated to tumor proliferation and VEGF expression,41 as
well as metastasis.42 Thus, based on these evidences we can
suppose that the pro-angiogenic effect of HOXB7 in MM cells
could also involve WNT5a overexpression together with VEGF
and other pro-angiogenic factor overproduction. Previous
evidence suggested that the use of antagonists or inhibitors of
a single pro-angiogenic factor as VEGF inhibitors had a minimal
activity in MM43 probably because of the redundant production
of angiogenic molecules by tumor cells. On the other hand
multitarget drugs as thalidomide have shown anti-angiogenic
and anti-MM activity in MM patients. Interestingly, it has been
recently reported that thalidomide inhibits HOXB7-induced
gene expression in glioblastoma cell line.44 This evidence,
together with the capacity of HOXB7 to regulate cell prolifera-
tion and the production of several pro-angiogenic factors,
suggests that it might be an attractive therapeutic target for a
broad inhibition of angiogenic molecules and consequently of
the MM-induced angiogenesis.
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